Roche Refiles For US Antitrust Review Of $4.3B Spark Buy
Roche revealed Wednesday it will again refile with U.S. antitrust regulators for approval of its $4.3 billion takeover of gene therapy company Spark Therapeutics and said it will also give its...To view the full article, register now.
Already a subscriber? Click here to view full article